Skip to main content
Top
Published in: Drugs & Aging 5/2011

01-05-2011 | Original Research Article

Association between Glomerular Filtration Rate and Adverse Drug Reactions in Elderly Hospitalized Patients

The Role of the Estimating Equation

Authors: Dr Andrea Corsonello, Claudio Pedone, Fabrizia Lattanzio, Graziano Onder, Raffaele Antonelli Incalzi

Published in: Drugs & Aging | Issue 5/2011

Login to get access

Abstract

Background: Reduced renal function increases the risk of adverse drug reactions (ADRs) to hydrosoluble drugs (hADRs). However, the ability of different equations to calculate estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eCCr) and thereby predict the risk of developing hADRs has not previously been compared.
Objective: The aim of this study was to investigate which of three different equations for estimating renal function (Cockcroft-Gault [CG], Modification of Diet in Renal Disease [MDRD] and Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) was the most effective at predicting incident hADRs.
Methods: This multicentre study had an observational design and included 81 acute-care general (internal) or geriatric medicine wards in academic hospitals throughout Italy. Our series consisted of 10 442 hospitalized patients with a mean ± SD age of 70.2 ± 14.9 years enrolled in the GIFA study. The main outcome measures were incident ADRs during hospital stay. Data on these were collected and classified as hADRs or ADRs to liposoluble drugs (lADRs). Patients were grouped according to their eGFR (mL/min/1.73m2) or eCCr (mL/min): ≥90, 60–89.9, 45–59.9, 30–44.9 or <30.
Results: The multivariable adjusted risk of hADRs progressively increased with decreasing eGFR as determined by estimates of mL/min/1.73 m2 calculated using CKD-EPI (60–89.9: hazard ratio [HR] = 1.07 [95% CI 0.70, 1.72]; 45–59.9: HR = 1.62 [95% CI 1.0,2.69]; 30–44.9: HR = 2.13 [95% CI 1.24, 3.64]; <30: HR = 2.30 [95% CI 1.28, 4.14]) and, to a lesser extent, MDRD (60–89.9: HR = 1.15 [95% CI 0.75, 1.76]; 45–59.9: HR = 1.73 [95% CI 1.09, 2.73]; 30–44.9: HR = 2.14 [95% CI 1.30, 3.53]; <30: HR = 1.99 [95% CI 1.11, 3.57]) equations. The risk of hADRs also increased with lower eCCr, but only at CG eCCr <45mL/min (30–44.9: HR = 1.61 [95% CI 0.96, 2.77]; <30: HR = 1.76 [95% CI 1.0, 3.18]). Neither eGFR nor eCCr were associated with lADRs.
Conclusions: CKD-EPI-based estimates of eGFR outperformed MDRD-based estimates of eGFR and CG-based estimates of eCCr as a predictor of hADRs.
Literature
1.
go back to reference Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010 Feb 3; 303(5): 423–9PubMedCrossRef Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010 Feb 3; 303(5): 423–9PubMedCrossRef
2.
go back to reference Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 Sep 23; 351(13): 1296–305PubMedCrossRef Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 Sep 23; 351(13): 1296–305PubMedCrossRef
3.
go back to reference Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 Sep 23; 351(13): 1285–95PubMedCrossRef Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 Sep 23; 351(13): 1285–95PubMedCrossRef
4.
go back to reference Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005 Apr 11; 165(7): 790–5PubMedCrossRef Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005 Apr 11; 165(7): 790–5PubMedCrossRef
5.
go back to reference Hanratty CG, McGlinchey P, Johnston GD, et al. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 2000; 17(5): 353–62PubMedCrossRef Hanratty CG, McGlinchey P, Johnston GD, et al. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 2000; 17(5): 353–62PubMedCrossRef
6.
go back to reference Morike K, Schwab M, Klotz U. Use of aminoglycosides in elderly patients: pharmacokinetic and clinical considerations. Drugs Aging 1997; 10(4): 259–77PubMedCrossRef Morike K, Schwab M, Klotz U. Use of aminoglycosides in elderly patients: pharmacokinetic and clinical considerations. Drugs Aging 1997; 10(4): 259–77PubMedCrossRef
7.
go back to reference Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16(3): 165–77PubMedCrossRef Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16(3): 165–77PubMedCrossRef
8.
go back to reference Raveh D, Kopyt M, Hite Y, et al. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 2002 May; 95(5): 291–7PubMedCrossRef Raveh D, Kopyt M, Hite Y, et al. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 2002 May; 95(5): 291–7PubMedCrossRef
9.
go back to reference Pedone C, Corsonello A, Incalzi RA. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006 Mar; 35(2): 121–6PubMedCrossRef Pedone C, Corsonello A, Incalzi RA. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006 Mar; 35(2): 121–6PubMedCrossRef
10.
go back to reference Carosella L, Pahor M, Pedone C, et al. Pharmaco-surveillance in hospitalized patients in Italy. Study design of the ‘Gruppo Italiano di Farmacovigilanza nell’Anziano’ (GIFA). Pharmacol Res 1999 Sep; 40(3): 287–95PubMedCrossRef Carosella L, Pahor M, Pedone C, et al. Pharmaco-surveillance in hospitalized patients in Italy. Study design of the ‘Gruppo Italiano di Farmacovigilanza nell’Anziano’ (GIFA). Pharmacol Res 1999 Sep; 40(3): 287–95PubMedCrossRef
11.
go back to reference World Health Organization (WHO). International drug monitoring: the role of the hospital. Geneva: WHO, 1969. WHO Technical Report Series No.: 425 World Health Organization (WHO). International drug monitoring: the role of the hospital. Geneva: WHO, 1969. WHO Technical Report Series No.: 425
12.
go back to reference Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug; 30(2): 239–45PubMedCrossRef Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug; 30(2): 239–45PubMedCrossRef
13.
go back to reference Hardman GJ, Limbird LE, Goodman Gilman A. Goodman and Gilman’s: the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Co., 2001 Hardman GJ, Limbird LE, Goodman Gilman A. Goodman and Gilman’s: the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Co., 2001
14.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRef
15.
go back to reference Levey AS, Greene T, Kusek JW, et al., MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000; 11: A0828 Levey AS, Greene T, Kusek JW, et al., MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000; 11: A0828
16.
go back to reference Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 May 5; 150(9): 604–12PubMed Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 May 5; 150(9): 604–12PubMed
17.
go back to reference K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 Feb; 39(2 Suppl. 1): S1–266 K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 Feb; 39(2 Suppl. 1): S1–266
18.
go back to reference Coresh J, Auguste P. Reliability of GFR formulas based on serum creatinine, with special reference to the MDRD Study equation. Scand J Clin Lab Invest Suppl 2008; 241: 30–8PubMedCrossRef Coresh J, Auguste P. Reliability of GFR formulas based on serum creatinine, with special reference to the MDRD Study equation. Scand J Clin Lab Invest Suppl 2008; 241: 30–8PubMedCrossRef
19.
go back to reference Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963 Sep 21; 185: 914–9PubMedCrossRef Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963 Sep 21; 185: 914–9PubMedCrossRef
20.
go back to reference Rocca WA, Bonaiuto S, Lippi A, et al. Validation of the Hodkinson abbreviated mental test as a screening instrument for dementia in an Italian population. Neuroepidemiology 1992; 11(4–6): 288–95PubMedCrossRef Rocca WA, Bonaiuto S, Lippi A, et al. Validation of the Hodkinson abbreviated mental test as a screening instrument for dementia in an Italian population. Neuroepidemiology 1992; 11(4–6): 288–95PubMedCrossRef
21.
go back to reference PHS-HCF. International classification of diseases, 9th revision. Clinical modifications. Washington, DC: Public Health Service-Health Care Financing Administration, 1980 PHS-HCF. International classification of diseases, 9th revision. Clinical modifications. Washington, DC: Public Health Service-Health Care Financing Administration, 1980
22.
go back to reference Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef
23.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 Jun; 45(6): 613–9PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 Jun; 45(6): 613–9PubMedCrossRef
24.
go back to reference Pahor M, Chrischilles EA, Guralnik JM, et al. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994 Aug; 10(4): 405–11PubMedCrossRef Pahor M, Chrischilles EA, Guralnik JM, et al. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994 Aug; 10(4): 405–11PubMedCrossRef
25.
go back to reference Altman DG. Some common problems in medical research. Practical statistics for medical research. London: Chapman & Hall, 1997 Altman DG. Some common problems in medical research. Practical statistics for medical research. London: Chapman & Hall, 1997
26.
go back to reference Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 Apr; 143(1): 29–36PubMed Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 Apr; 143(1): 29–36PubMed
27.
go back to reference Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998 Dec; 32(6): 992–9PubMedCrossRef Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998 Dec; 32(6): 992–9PubMedCrossRef
28.
go back to reference Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 2009 Feb; 57(2): 335–40PubMedCrossRef Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 2009 Feb; 57(2): 335–40PubMedCrossRef
29.
go back to reference Corsonello A, Pedone C, Corica F, et al. Concealed renal failure and adverse drug reactions in older patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci 2005 Sep; 60(9): 1147–51PubMedCrossRef Corsonello A, Pedone C, Corica F, et al. Concealed renal failure and adverse drug reactions in older patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci 2005 Sep; 60(9): 1147–51PubMedCrossRef
30.
go back to reference Corsonello A, Pedone C, Corica F, et al. Estimating glomerular filtration rate might help to avoid hypoglycemia. J Am Geriatr Soc 2006 Sep; 54(9): 1469–70PubMedCrossRef Corsonello A, Pedone C, Corica F, et al. Estimating glomerular filtration rate might help to avoid hypoglycemia. J Am Geriatr Soc 2006 Sep; 54(9): 1469–70PubMedCrossRef
31.
go back to reference Farrell B, Pottie K, Hogg W. Case report: adverse drug reactions in unrecognized kidney failure. Can Fam Physician 2004 Oct; 50: 1385–7PubMed Farrell B, Pottie K, Hogg W. Case report: adverse drug reactions in unrecognized kidney failure. Can Fam Physician 2004 Oct; 50: 1385–7PubMed
32.
go back to reference Landi F, Onder G, Gambassi G, et al. Body mass index and mortality among hospitalized patients. Arch Intern Med 2000 Sep 25; 160(17): 2641–4PubMedCrossRef Landi F, Onder G, Gambassi G, et al. Body mass index and mortality among hospitalized patients. Arch Intern Med 2000 Sep 25; 160(17): 2641–4PubMedCrossRef
33.
go back to reference Onder G, Landi F, Volpato S, et al. Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med 2003 Sep; 115(4): 265–71PubMedCrossRef Onder G, Landi F, Volpato S, et al. Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med 2003 Sep; 115(4): 265–71PubMedCrossRef
34.
go back to reference Matsushita K, Selvin E, Bash LD, et al. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010 Apr; 55(4): 648–59PubMedCrossRef Matsushita K, Selvin E, Bash LD, et al. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010 Apr; 55(4): 648–59PubMedCrossRef
35.
go back to reference White SL, Polkinghorne KR, Atkins RC, et al. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010 Apr; 55(4): 660–70PubMedCrossRef White SL, Polkinghorne KR, Atkins RC, et al. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010 Apr; 55(4): 660–70PubMedCrossRef
36.
go back to reference Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60mL/min/1.73m2. Am J Kidney Dis 2010 Sep; 56(3): 486–95PubMedCrossRef Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60mL/min/1.73m2. Am J Kidney Dis 2010 Sep; 56(3): 486–95PubMedCrossRef
37.
go back to reference El-Ghoul B, Elie C, Sqalli T, et al. Nonprogressive kidney dysfunction and outcomes in older adults with chronic kidney disease. J Am Geriatr Soc 2009 Dec; 57(12): 2217–23PubMedCrossRef El-Ghoul B, Elie C, Sqalli T, et al. Nonprogressive kidney dysfunction and outcomes in older adults with chronic kidney disease. J Am Geriatr Soc 2009 Dec; 57(12): 2217–23PubMedCrossRef
38.
go back to reference Douville P, Martel AR, Talbot J, et al. Impact of age on glomerular filtration estimates. Nephrol Dial Transplant 2009 Jan; 24(1): 97–103PubMedCrossRef Douville P, Martel AR, Talbot J, et al. Impact of age on glomerular filtration estimates. Nephrol Dial Transplant 2009 Jan; 24(1): 97–103PubMedCrossRef
39.
go back to reference Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 2010; 17(6): 571–84PubMedCrossRef Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 2010; 17(6): 571–84PubMedCrossRef
Metadata
Title
Association between Glomerular Filtration Rate and Adverse Drug Reactions in Elderly Hospitalized Patients
The Role of the Estimating Equation
Authors
Dr Andrea Corsonello
Claudio Pedone
Fabrizia Lattanzio
Graziano Onder
Raffaele Antonelli Incalzi
Publication date
01-05-2011
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 5/2011
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11588280-000000000-00000

Other articles of this Issue 5/2011

Drugs & Aging 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine